Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 4/20 | 0.47 |
| ▸ | IL2 | P60568 | 3/20 | 0.45 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | POLB | P06746 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | ABL1 | P00519 | 1/20 | 0.43 |
| ▸ | STIM1 | Q13586 | 2/20 | 0.42 |
| ▸ | ORAI1 | Q96D31 | 2/20 | 0.42 |
| ▸ | GAA | P10253 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
| ▸ | NPC1 | O15118 | 3/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.42 |
| ▸ | TP53 | P04637 | 1/20 | 0.42 |
| ▸ | WNT3A | P56704 | 1/20 | 0.42 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.41 |
| ▸ | FYN | P06241 | 1/20 | 0.41 |
| ▸ | MET | P08581 | 2/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12155522 | 0.91 | STIM1 (0.54) | RAB9AMEN1KMT2AABL1STIM1 | |
| SCHEMBL12156018 | 0.88 | STIM1 (0.53) | RAB9AIL2MEN1KMT2AABL1 | |
| SCHEMBL12156011 | 0.88 | IL2 (0.50) | RAB9AIL2MEN1POLBKMT2A | |
| SCHEMBL12156187 | 0.85 | IL2 (0.49) | RAB9AIL2MEN1KMT2ASTIM1 | |
| SCHEMBL12155570 | 0.84 | IL2 (0.48) | RAB9AIL2MEN1POLBKMT2A | |
| SCHEMBL12155563 | 0.84 | DYRK1A (0.47) | RAB9AMEN1KMT2ASTIM1ORAI1 | |
| SCHEMBL12155539 | 0.84 | STIM1 (0.52) | RAB9AIL2MEN1KMT2ASTIM1 | |
| SCHEMBL12155532 | 0.82 | IL2 (0.47) | RAB9AIL2MEN1KMT2ASTIM1 | |
| SCHEMBL12156189 | 0.81 | IL2 (0.54) | IL2ABL1STIM1ORAI1 | |
| SCHEMBL12155566 | 0.80 | IL2 (0.45) | RAB9AIL2MEN1POLBKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200317617-A1 | COMPOUNDS THAT MODULATE INTRACELLULAR CALCIUM | AVENUE CAPITAL MANAGEMENT II, L.P. | 2020-10-08 | — | — | US | disclosed |
| US-10703722-B2 | Compounds that modulate intracellular calcium | CALCIMEDICA, INC. (US) | 2020-07-07 | — | — | US | disclosed |
| EP-2563776-B1 | COMPOUNDS THAT MODULATE INTRACELLULAR CALCIUM | CALCIMEDICA INC (US) | 2016-06-08 | — | — | EP | disclosed |
| US-20150322012-A1 | COMPOUNDS THAT MODULATE INTRACELLULAR CALCIUM | AVENUE CAPITAL MANAGEMENT II, L.P. | 2015-11-12 | — | — | US | disclosed |
| US-9120751-B2 | Compounds that modulate intracellular calcium | CALCIMEDICA, INC. (US) | 2015-09-01 | — | — | US | disclosed |
| US-9120751-B2 | Compounds that modulate intracellular calcium | CALCIMEDICA, INC. (US) | 2015-09-01 | — | — | US | disclosed |
| US-8980629-B2 | Compounds that modulate intracellular calcium | CALCIMEDICA, INC. (US) | 2015-03-17 | — | — | US | disclosed |
| US-8980629-B2 | Compounds that modulate intracellular calcium | CALCIMEDICA, INC. (US) | 2015-03-17 | — | — | US | disclosed |
| US-8546403-B2 | Compounds that modulate intracellular calcium | CALCIMEDICA, INC. (US) | 2013-10-01 | — | — | US | disclosed |
| WO-2011139489-A2 | COMPOUNDS THAT MODULATE INTRACELLULAR CALCIUM | CALCIMEDICA INC. (US) | 2011-11-10 | — | — | WO | disclosed |
| US-20110263612-A1 | COMPOUNDS THAT MODULATE INTRACELLULAR CALCIUM | CALCIMEDICA, INC. (US) | 2011-10-27 | — | — | US | disclosed |
| US-20110263612-A1 | COMPOUNDS THAT MODULATE INTRACELLULAR CALCIUM | CALCIMEDICA, INC. (US) | 2011-10-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150322012-A1 | COMPOUNDS THAT MODULATE INTRACELLULAR CALCIUM | ORAI1, SARAF, RYR2 | RAB9A 1174/4885IL2 3716/4885MEN1 2958/4885 |
| US-10703722-B2 | Compounds that modulate intracellular calcium | ORAI1, SARAF, RYR2 | RAB9A 1174/4885IL2 3716/4885MEN1 2958/4885 |
| US-20110263612-A1 | COMPOUNDS THAT MODULATE INTRACELLULAR CALCIUM | ORAI1, SARAF, RYR2 | RAB9A 1174/4885IL2 3716/4885MEN1 2958/4885 |
| US-20200317617-A1 | COMPOUNDS THAT MODULATE INTRACELLULAR CALCIUM | ORAI1, SARAF, RYR2 | RAB9A 1174/4885IL2 3716/4885MEN1 2958/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.